Activation of the Kynurenine Pathway in Human Malignancies Can Be Suppressed by the Cyclin-Dependent Kinase Inhibitor Dinaciclib
Christin Riess, Björn Schneider, Hanna Kehnscherper, Julia Gesche, Nina Irmscher, Fatemeh Shokraie, Carl Friedrich Classen, Elisa Wirthgen, Grażyna Domańska, Annette Zimpfer, Daniel Strüder, Christian Junghanß, Claudia Maletzki
Abstract
) were induced. Vice versa, the novel yet experimental cyclin-dependent kinase inhibitor Dinaciclib suppressed KP in both entities. Our comprehensive data imply inhibition of the TRP catabolism by Dinaciclib, while conventional chemotherapeutics tend to activate this pathway. These data point to limitations of conventional therapy and highlight the potential of targeted therapies to interfere with the cells' metabolism more than anticipated.
Topics & Concepts
Cancer researchKynurenine pathwayKynurenineCetuximabIndoleamine 2,3-dioxygenaseKinaseChemistryCancerBiologyMedicineInternal medicineTryptophanBiochemistryAmino acidColorectal cancerTryptophan and brain disordersCancer-related cognitive impairment studiesBipolar Disorder and Treatment